| Market Cap | 1.34B | P/E | - | EPS this Y | 31.70% | Ern Qtrly Grth | - |
| Income | -94.66M | Forward P/E | -14.25 | EPS next Y | 26.20% | 50D Avg Chg | - |
| Sales | - | PEG | -0.19 | EPS past 5Y | - | 200D Avg Chg | 63.00% |
| Dividend | N/A | Price/Book | 5.00 | EPS next 5Y | 59.80% | 52W High Chg | - |
| Recommedations | 2.70 | Quick Ratio | 8.14 | Shares Outstanding | 24.42M | 52W Low Chg | 269.00% |
| Insider Own | 8.52% | ROA | -54.52% | Shares Float | 9.65M | Beta | 0.57 |
| Inst Own | 66.68% | ROE | -97.61% | Shares Shorted/Prior | 2.29M/1.21M | Price | 54.99 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 651,457 | Target Price | 55.00 |
| Oper. Margin | - | Earnings Date | May 5 | Volume | Change | 0.00% |
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.
| Jefferies | Hold | Apr 14, 22 |
| Oppenheimer | Perform | Apr 14, 22 |
| HC Wainwright & Co. | Neutral | Apr 13, 22 |
| Oppenheimer | Outperform | Mar 14, 22 |
| HC Wainwright & Co. | Buy | Jan 31, 22 |
| Cantor Fitzgerald | Overweight | Nov 30, 21 |
| HC Wainwright & Co. | Buy | Nov 5, 21 |
| Cantor Fitzgerald | Overweight | Sep 27, 21 |
| HC Wainwright & Co. | Buy | Nov 25, 20 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Thomson Mary Christina | General Counsel, CCO.. General Counsel, CCO & Sec'y | Apr 04 | Option | 13.04 | 2,000 | 26,080 | 2,000 | 04/04/22 |
| Thomson Mary Christina | General Counsel, CCO.. General Counsel, CCO & Sec'y | Apr 04 | Sell | 35.14 | 2,000 | 70,280 | 04/04/22 | |
| Turner William D. | Chief Reg & Tech Ops.. Chief Reg & Tech Ops Officer | Mar 17 | Option | 12.05 | 3,453 | 41,609 | 3,453 | 03/17/22 |
| Turner William D. | Chief Reg & Tech Ops.. Chief Reg & Tech Ops Officer | Mar 17 | Sell | 37.06 | 3,453 | 127,968 | 03/17/22 | |
| Longitude Capital Partners III... | 10% Owner 10% Owner | Jan 31 | Buy | 27.00 | 175,000 | 4,725,000 | 175,000 | 02/02/22 |
| Richardson Joshua | Director Director | Jan 31 | Buy | 27.00 | 175,000 | 4,725,000 | 175,000 | 02/02/22 |
| Sinclair Andrew | Director Director | Jan 28 | Buy | 27 | 150,000 | 4,050,000 | 1,314,127 | 02/01/22 |
| Abingworth LLP | 10% Owner 10% Owner | Jan 28 | Buy | 27 | 150,000 | 4,050,000 | 1,314,127 | 02/01/22 |
| Vivo Opportunity, LLC | 10% Owner 10% Owner | Jan 31 | Buy | 27 | 800,000 | 21,600,000 | 2,735,853 | 01/31/22 |
| Aggarwal Gaurav | Director Director | Jan 31 | Buy | 27.00 | 800,000 | 21,600,000 | 2,735,853 | 01/31/22 |
| Thomson Mary Christina | General Counsel & Se.. General Counsel & Secretary | Jan 26 | Option | 13.04 | 2,000 | 26,080 | 2,000 | 01/28/22 |
| Thomson Mary Christina | General Counsel & Se.. General Counsel & Secretary | Jan 26 | Sell | 29 | 2,000 | 58,000 | 01/28/22 |